Twitter Facebook Website

Columbia University Medical Center

Programs Featuring Experts from Columbia University Medical Center (14)

Exploring Second-Generation CLL Inhibitors

Philip Thompson, MB, BS, Andrew Schorr, Nicole Lamanna, MD

Checkpoint Inhibitors and CLL

Andrew Schorr, Nicole Lamanna, MD

When Should Transplant Be Considered for CLL Patients?

Philip Thompson, MB, BS, Andrew Schorr, Nicole Lamanna, MD

The Goal of Myelofibrosis (MF) Treatment

John Mascarenhas, MD, Andrew Schorr

The Goal of Essential Thrombocythemia (ET) Treatment

John Mascarenhas, MD, Andrew Schorr

Treating Polycythemia Vera (PV) With Phlebotomy

Mark Heaney, MD, PhD, Andrew Schorr

Why Is Venetoclax Approved for Only a Subset of Patients?

Philip Thompson, MB, BS, Andrew Schorr, Nicole Lamanna, MD

Assessing the Risk for Progression in MPNs

Mark Heaney, MD, PhD, Andrew Schorr

Everyone's MPN Is Different: Finding the Best Treatment Plan for You

John Mascarenhas, MD, Mark Heaney, MD, PhD, Andrew Schorr

Expert Update: The Status of JAK Inhibitors in Development

John Mascarenhas, MD, Mark Heaney, MD, PhD, Andrew Schorr

How Do CLL Inhibitor Treatments Work?

Andrew Schorr, Nicole Lamanna, MD

Is Occasional Spleen Pain Normal for an MPN Patient Without Splenomegaly?

Mark Heaney, MD, PhD, Andrew Schorr